fermenta biotech has been ranked 7th nationwide in the Top 50 category as part of India's Great Mid-size Workplaces 2026 by Great Place To Work. This recognition highlights the company's strong people-first culture and high-trust workplace environment, achieved during its 75-year milestone of trust, science, and service. The ranking is based on employee feedback and a rigorous workplace culture assessment conducted by Great Place To Work India.

Over 2,000 organizations partnered with Great Place To Work India this year to assess and benchmark their workplace culture. Securing the 7th position across a wide range of sectors reflects the culture Fermenta Biotech Limited has built over the years. This achievement follows the company's recent recognition among India's Best Workplaces in Pharmaceuticals, Healthcare and Biotech 2025, reaffirming its commitment to nurturing an empowering environment for employees.

Comment from Leadership

Prashant Nagre, Managing Director, attributed the recognition to the team members and partners. He stated that the ranking belongs to every team member who brings commitment and ownership to work daily. Nagre emphasized that as the company celebrates 75 years, this achievement reflects a culture rooted in trust, responsibility, and collaboration.

Key Recognition Details

Fermenta Biotech Limited delivers science-validated nutritional ingredients across pharmaceuticals, dietary supplements, and other industries. Its manufacturing facilities are located in Kullu, Dahej, and Tirupati, supported by an R&D Excellence Centre in Thane.

Fermenta Biotech Limited will hold a one-to-one investor meeting on June 26, 2026, in Mumbai to discuss its audited financial results for the year ended March 31, 2026. The meeting is part of the company's ongoing investor relations efforts and will be conducted in physical mode. This interaction provides a platform for the company to present its financial performance and strategic outlook directly to investors.

The company stated that the discussion will focus on the audited financial results for FY26 and the associated investor presentation. Both documents have been uploaded to the company's official website and the BSE Limited website for investor reference. The meeting details were communicated to the stock exchange pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Fermenta Biotech clarified that no unpublished price sensitive information (UPSI) is intended to be discussed during the interaction. The company also noted that changes to the schedule may occur due to exigencies on the part of the company or investors. The intimation was signed by Varadvinayak Khambete, Company Secretary & Head – Legal.

The meeting follows the release of the company's audited financial results for the fiscal year ending March 31, 2026. Investors can access the detailed results and the investor presentation on the company's website to prepare for the discussion.